Sponsorship & Exhibition

For details regarding sponsorship and exhibition opportunities and the latest prospectus, please contact Stacey Lawrence: stacey@soafrica.com | +27 (0)11 463 5085

Dear colleagues, friends, and partners,

It is with great enthusiasm that I invite you to partner with us for HaemOnc 2026, to be held in Cape Town under the theme “Beyond Boundaries: From Progress to Access.” This theme speaks directly to the challenge facing modern haematology and oncology in South Africa: ensuring that scientific advances translate into equitable, sustainable access to diagnostics and treatment.

The past few years has seen remarkable progress in therapeutics, molecular diagnostics, and precision medicine. Nevertheless, access remains uneven, not only in the public sector, but also for many private patients with medical aids. HaemOnc 2026 will address this reality head-on by fostering practical, solution-focused dialogue around implementation, affordability, and system-level integration.

The scientific programme will integrate clinical and laboratory perspectives, with strong emphasis on diagnostics, molecular pathology, and emerging technologies. Sessions will combine local case-based discussions with international expertise, encouraging thoughtful engagement across the full patient-care pathway.

As always, industry partnership is absolutely fundamental to the success of the conference. Your involvement as a sponsor or exhibitor enables us to provide a high-quality conference, with world-class speakers and opportunities for meaningful exchange and collaborative problem-solving. We value these partnerships deeply and see them as essential to advancing care for patients across South Africa and the region.

We invite you to explore the sponsorship and exhibition opportunities outlined in this prospectus and to join us on the journey toward HaemOnc 2026. We look forward to engaging with you at the Sponsorship and Exhibition Trade Launch and throughout the planning of what promises to be a highly relevant and forward-looking meeting.

Kind regards
Vernon Louw
President: South African Clinical Haematology Society (SACHaS)

To request the sponsorship and exhibition prospectus please complete the form below

About AstraZeneca

AstraZeneca is a science-led, patient-focused biopharmaceutical company committed to transforming healthcare and improving outcomes. We believe science, powered by digital, data and AI, is key to addressing the world’s most pressing healthcare challenges.

We strive to improve access to life-changing medicines and pioneering solutions, while also supporting earlier detection, integrated care pathways, and stronger health systems so more people can receive the right care at the right time. Powered by scientific innovation, and increasingly enabled by digital, data and AI, we are helping redefine cancer care, improve outcomes in chronic diseases, and expand access to care in a sustainable and responsible way.

Activity ID: ZA-6886; Expiry date: 30 June 2028

https://www.astrazeneca.com/country-sites/african-cluster.html

About Novo Nordisk

Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built on our heritage in diabetes. Through scientific innovation, expanded access to medicines, and partnerships across healthcare and technology, we help bring meaningful solutions to patients worldwide. Novo Nordisk employs about 67,900 people in 80 countries and markets its products in around 170 countries. For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.

Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach 304 million people worldwide.

Reimagine medicine with us: Visit us at https://www.novartis.com and connect with us on LinkedIn, Facebook, X/Twitter, Instagram and YouTube.

Loading...